Eli Lilly Entered into New Research and Collaboration Agreement with PeptiDream to Discover Novel Peptide Drug Conjugates
Shots:
- PeptiDream to receive an up front, ~$1.235B upon achievement of development, regulatory & commercial milestones along with royalties. The new agreement was based on the 2013 collaboration which was followed by the Mar 2016 nonexclusive license of PeptiDream’s PDPS technology that excludes work on PDC programs
- PeptiDream will lead the peptide discovery & optimization efforts. Lilly will lead payload discovery & optimization efforts along with development aspects of any PDC products
- The collaboration focus is to identify the high-affinity macrocyclic peptide ligands for TOI (chosen by Lilly) & deliver a Lilly-conjugated payload to specific cells and tissues using PeptiDream’s PDPS technology
Ref: Businesswire | Image: Eli Lilly
Related News:- Eli Lilly Expands its 2021 Agreement with ProQR Therapeutics for New Genetic Therapies
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
